Can a Faecal Transplant Help Treat Parkinson’s? New Research Says Yes

A new study out of Ghent University Hospital in Belgium is making waves in the Parkinson’s research world — not for what it found in the brain, but for what it uncovered in the gut. It suggests that tweaking the gut microbiome — the community of trillions of bacteria living in your digestive tract — could actually slow the progression of Parkinson’s symptoms. 🔍 What Did the Study Involve? Researchers ran a double-blind, placebo-controlled clinical trial — the gold standard in research — involving 47 people with early-stage Parkinson’s disease. Over 12 weeks, participants were randomly given either a microbiota-targeting treatment (a combination of antibiotics and bowel cleansing followed by a faecal microbiota transplant or FMT) or a placebo. The FMT came from healthy donors, aiming to “reset” the gut microbiome. Participants were followed up for 6 months to see whether any improvements stuck. 📈 The Results? Those who received the gut-focused treatment showed a significantly slower decline in motor function over the 6-month follow-up compared to those in the placebo group. What’s especially noteworthy is: Motor symptoms (measured using the MDS-UPDRS Part III) stabilised or improved in the treatment group. The microbiota profile of these participants shifted closer to that of the healthy donors, suggesting a long-lasting effect on gut bacteria. Some non-motor symptoms, like constipation, also improved. 🧠 Why This Matters This is one of the first studies in people with Parkinson’s to show that directly altering the gut microbiome might influence the course of the disease — not just symptoms, but potentially the underlying progression. This supports earlier findings from animal studies, where mice that received gut bacteria from Parkinson’s patients developed motor symptoms, and those raised without gut bacteria fared better. 💬 So, Should You Try a Gut Cleanse or Probiotics? Not quite — this isn’t medical advice, and the treatment used in this study isn’t yet available outside clinical trials. But the results open doors. The researchers suggest: Future Parkinson’s therapies could include gut-targeting treatments alongside traditional dopamine-based meds. FMTs, if proven safe and effective in larger trials, might one day be used to complement existing Parkinson’s care. Diet, prebiotics, probiotics, and antibiotics may play a bigger role in personalised treatment plans — but more research is needed to define what works best, for whom, and when. 🧭 What’s Next? A larger Phase 2 trial is being planned to confirm these findings. The researchers also hope to pinpoint exactly which bacteria (or combinations) are doing the heavy lifting — so future treatments could be more precise than a full FMT. For now, this study is a sign that gut health might not just be about digestion — for people with Parkinson’s, it might also be a key to slowing the disease.